Solesence, Inc. (SLSN) enters its Q2 2026 report with no formal analyst consensus for revenue or EPS, though management's full-year guidance suggests a recovery from the $13 million revenue reported in the prior quarter. The stock currently trades near $0.93, and while no unified analyst price target is available due to limited coverage, recent volatility has seen the price test key support levels below $1.00.
Investors are laser-focused on the company's gross margin percentage, as management has established a firm "30% floor" target for the 2026 fiscal year.
This report is critical to determine if "on-time-in-full" (OTIF) shipping issues, which caused a year-over-year revenue decline in Q1, have normalized to allow the company to fulfill its $47 million backlog of open orders. Management’s "Transform and Transcend" initiative remains the core narrative as the company strives to restore double-digit EBITDA margins by year-end.